PD-1
7 drugsProgrammed Cell Death Protein 1
Predictive biomarker for patient selection in 13 indications
Understanding PD-1
What it means: PD-1 is an immune checkpoint receptor on T cells. When bound by PD-L1, it suppresses T cell activity, allowing cancer to evade immune attack.
Why it matters: Anti-PD-1 antibodies (pembrolizumab, nivolumab) block this interaction, reactivating T cells to attack tumors. Used across many cancer types.
Testing: PD-1 status is typically assessed via PD-L1 expression testing on tumor tissue (IHC). PD-L1 levels help predict response.
7
Approved Drugs
13
Indications
7
Companies
PD-1 is a precision-medicine biomarker linked to 7 FDA-approved targeted drugs from 7 companies, spanning 13 indications including Squamous Cell Carcinoma of the Anal Canal, Merkel Cell Carcinoma, Esophageal Cancer. Explore the targeted therapies, indications, testing methods, and companies developing PD-1 drugs below.
Search PD-1 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PD-1
| Drug | Company | Therapeutic Area |
|---|---|---|
| JEMPERLI | GSK | Oncology |
| KEYTRUDA QLEX | Merck | Oncology |
| LOQTORZI | COHERUS BIOSCIENCES INC | Oncology |
| OPDUALAG | Bristol-Myers Squibb | Oncology |
| PENPULIMAB-KCQX | AKESO BIOPHARMA | Oncology |
| TEVIMBRA | BEIGENE | Oncology |
| ZYNYZ | INCYTE CORP | Oncology |
PD-1 Indications
Squamous Cell Carcinoma of the Anal Canal Merkel Cell Carcinoma Esophageal Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Melanoma Non-Small Cell Lung Cancer Unresectable melanoma Metastatic melanoma Nasopharyngeal Carcinoma Endometrial Cancer Solid Tumors